The present work examined the potential of utilizing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in both p53 wild-type (WT) breast tumor cells and in cells missing practical p53 either by itself or in combination with tamoxifen, when the effectiveness of https://zbignieww009hrd2.blog4youth.com/profile